The purpose of this study is to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in subjects with certain cancers. This study will be conducted in 2 phases, Phase 1 and Phase 2.
Name: MK-3475
Description: IV infusionType: DrugPhase 1: MK-3475 + INCB024360 Phase 2: MK-3475 + INCB024360
Name: INCB024360
Description: Oral daily dosingType: DrugPhase 1: MK-3475 + INCB024360 Phase 2: MK-3475 + INCB024360
Allocation: Non-Randomized
Parallel Assignment
There is one SNP
- Phase 2 expansion: Melanoma - Documentation of V600E-activating BRAF mutation status. --- V600E ---